Pertussis epidemiological pattern and disease burden in Brazil: an analysis of national public health surveillance data

Eliana Nogueira Castro De Barrosa, Altacilio Aparecido Nunaeb, Ariane De Jesus Lopes De Abreu, Bárbara Emoingt Furtadoa, Otavio Cintra, Monica Act Cintra, and Eduardo Barbosa Coelho

Objective: We described pertussis epidemiological trends in Brazil between 2010 and 2015. We also assessed tetanus, diphtheria and acellular pertussis (Tdap) vaccine coverage among pregnant women from 2014, the year of the introduction of Tdap maternal immunization recommendation in Brazil, to 2016.

Methods: Epidemiological data for incidence, prevalence, hospitalization, mortality, and maternal vaccination coverage were calculated based on the Brazilian public surveillance databases.

Results: The epidemiological data analysis results showed that the pertussis average incidence rate (IR) was 2.19/100,000 inhabitants for all ages, with a peak in 2014 (4.03/100,000 inhabitants) and highest incidence in <1-year-old children (IR = 175.20/100,000). 97.6% of pertussis deaths (405/415) were in <1-year-old children. Maternal immunization coverage was 9.2% in 2014, 40.4% in 2015, and 33.8% in 2016.

Conclusions: Pertussis incidence and pertussis-related deaths increased in Brazil from 2010 to 2014 and decreased in 2015. In the two years, 2015 and 2016 that followed the NIP recommendation, Tdap vaccination coverage of pregnant women was low and varying from region to region. More efforts and national plans would help increase awareness and maternal immunization coverage.

Introduction

Pertussis (whooping cough) is a highly contagious respiratory disease caused by the human-restricted pathogen Bordetella pertussis. The infection is transmitted with droplets spread by coughing, sneezing, or speaking. The incubation period lasts 7 to 10 days and then the illness develops for 6 to 12 weeks through three phases: catarrhal, paroxysmal, and convalescent. Its typical clinical course in unimmunized children begins with respiratory symptoms and a gradual worsening of the cough, progressing to the characteristic paroxysms followed by whooping and post-tussive vomiting. Apnea and cyanosis are among the initial symptoms in children ≤1 year of age that may lead to seizures, and also severe pulmonary hypertension, resulting in death. If untreated, the infected person is highly contagious for up to three weeks. The disease is transmitted to children ≤1 year of age especially by their mothers, and to a lesser extent by their fathers and grandparents.

Immunity to pertussis can be acquired after the disease or after vaccination, however the protection wanes over time. The Brazilian National Immunization Program (NIP) recommends immunization with diphtheria, tetanus and whole cell pertussis vaccine (DTP) at two, four, six and 15 months of age, with a booster between four and six years of age. Furthermore, because maternal immunization has been shown to be effective in protecting babies from pertussis until the completion of their primary vaccination, the Brazilian NIP has been recommending, since 2014, booster with reduced antigen content of tetanus, diphtheria, and acellular pertussis vaccine (Tdap) for pregnant women starting from the 27th week of gestation. In Brazil, all population has free of charge vaccination offered by the NIP. Updated recommendations issued in 2017 state that vaccination should start from the 20th week of each pregnancy. Women who missed the opportunity to be vaccinated during pregnancy should receive a dose of Tdap in the post-partum as early as possible (within less than 45 days post-partum).

Despite achieving approximately 85% global coverage since 2010 with three DTP doses, a resurgence of pertussis in recent years was observed. Pertussis epidemiological pattern usually presents in cycles with incidence peaking every 3–5 years; however, in some countries, the pertussis incidence increases represented a true resurgence of the disease. In Brazil, analyzed surveillance data 2007–2014 showed that pertussis had re-emerged in Brazil. Of the confirmed cases, 34.5% were in patients aged ≤2 months of age, 22.4% were in patients aged from 3 to 6 months of age, and 21% in patients aged 7 months to 4 years old. The overall case fatality rate was 2.1%, and was higher in children <3 months of age (4.7%). The expected vaccination coverage of 95% with three DTP doses was reached only in nine of the 27 Brazilian states (26 states and the

CONTACT Ariane Abreu ariane.j.abreu@gsk.com GSK, Estrada Dos Bandeirantes 8464, Jacarepaguá, Rio de janeiro 22783110

© 2019 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Federal district) in 2012, but this number was increased to 17 in 2013 and 21 in 2014.20

In this context, based on the fact that the surveillance of the evolution of pertussis epidemiology needs to be reviewed regularly and considering the re-emergence of pertussis as a potential public health problem for Brazil, it is important to examine and update with the most recent data the epidemiological information for pertussis in Brazil in order to better address and evaluate strategies for disease control, such as maternal immunization. The aim of this study was: to describe pertussis epidemiological trends in Brazil between 2010 and 2015 based on the pertussis surveillance data of the national public health databases (see Figure 1). The current analysis included periods before and one year after Tdap maternal immunization recommendation by NIP in 2014.

**Results**

Overall, 26,086 pertussis cases were reported in the period 2010–2015, 15,703 hospitalizations, and 415 deaths due to pertussis (Table 1). Children <1 year of age accounted for 61.9% (16,150/26,086) of all cases; 15.6% (4,060/26,086) were from 1 year to 4 years of age and 22.5% (5,876/26,086) were >4 years of age.

**Pertussis cases and incidence rates**

The highest mean incidence rate, in the overall population (all ages) from 2010 to 2015, was reported in the South region (Table 1). The highest number of pertussis cases, pertussis-related hospitalizations, and deaths was reported in the Southeast (Table 1). The differences between proportions of pertussis cases, pertussis-related hospitalizations, and deaths were statistically significant lower in all comparisons between each region and the Southeast region that had the highest respective proportions. Five states had the highest absolute number of pertussis cases during the studied period: São Paulo (6,430), Espírito Santo (2,771), Paraná (2,389), Pernambuco (2,145) and Rio Grande do Sul (1,916).

The number of pertussis cases in young children during the study period is shown in Figure 2(a). The mean incidence rate for the period 2010–2015 in the total population was

![Focus on the Patient](image)

**What is the context?**

Considering the re-emergence of pertussis as a potential public health problem, it is important to review and update with the most recent data the epidemiological information for pertussis in order to better address and evaluate strategies for disease control, such as maternal immunization.

**What is new?**

This is the most recent analysis of the public health surveillance data on pertussis epidemiology in Brazil and the first study to assess maternal immunization coverage in a short period after its introduction.

**What is the impact?**

Pertussis is still an important health problem in Brazil with an incidence that was progressively increased from 2010 to 2014, and resulted in high hospitalization rates. The maternal immunization coverage was low and did not exceed 50% in the two years after introduction. This is undoubtedly a worrying situation, considering that pertussis mainly affected children <1 year of age. Improving vaccination strategies are among the key factors towards controlling pertussis.

Table 1. Number of pertussis cases, hospitalizations and deaths, mean incidence rate per 100,000 inhabitants, prevalence rate per 100,000 inhabitants, and median case fatality rate, in Brazil and by region from 2010 to 2015.

| Region        | Pertussis cases | Hospitalizations due to pertussis | Deaths due to pertussis | Mean incidence rate | Prevalence rate | Case fatality rate |
|---------------|-----------------|----------------------------------|-------------------------|---------------------|-----------------|-------------------|
|               | N (%)           | N (%)                            | All ages, N (%) in all deaths |                      |                 |                   |
| Brazil        | 26,086 (100)    | 15,703 (100)                     | 415 (100)                | 2.19                | 13.01           | 1.90†             |
| Southeast     | 11,506 (45)     | 6,111 (39)                       | 175 (42)                 | 2.28*               | 13.88*          | 1.60†             |
| Northeast     | 6,081 (24)*     | 4,142 (26)*                      | 99 (24)*                 | 1.81†               | 10.93†          | 1.75*             |
| South         | 5,254 (21)*     | 2,863 (18)*                      | 49 (12)*                 | 2.75                | 18.55           | 0.93†             |
| Midwest       | 1,930 (8)*      | 1,351 (9)*                       | 52 (12)*                 | 2.23                | 13.58*          | 2.37†             |
| North         | 1,315 (2)*      | 1,236 (8)*                       | 40 (10)*                 | 1.67†               | 10.31†          | 2.30†             |

Source data: SINAN,21 SIH,22 SIM23

Footnote: *average incidence per 100,000 inhabitants; †calculated as follows: number of deaths/number of pertussis cases in each region; *p < 0.05 (each of the Brazilian regions compared to the Southeast Region; X² test); †p < 0.05 (each of the Brazilian regions compared to the South Region; Student t-test for independent samples); ‡p < 0.05 (All ages compared to the children <1 year of age; Brazil and between each of the Brazilian regions; Student t-test for independent samples)
2.19 per 100,000 inhabitants (Table 1). From 2010 to 2014, there was a marked increase in pertussis incidence in children <1 year of age (from 12.82 per 100,000 inhabitants in 2010 to 175.20 in 2014) followed by a reduction in 2015 (Figure 2(b)).

In all regions, the incidence of the disease in children <1 year of age was very high from 2011 to 2014 (Figure 3). The South region was the first to reach its highest incidence rate per 100,000 children <1 year of age, in 2012, followed by the Southeast region in 2013 – all other regions reached their highest incidence level in 2014 (Figures 3 & 4). Figure 4 graphically displays the maximum increases from 2010 in the incidence of pertussis infection in children <1 year age, by geographical region: the number in the parenthesis represents the year with the highest incidence (peak year) and the number before the parenthesis corresponds to the number of times that the incidence was increased from 2010 to the peak year.

**Hospitalizations and deaths**

Overall 15,703 hospitalizations due to pertussis were reported (Table 1). Considering that each case of pertussis generated only one hospitalization episode, the percentages of
Hospitalizations for the disease in Brazil were 60.2% (15,703/26,086); North 94.0% (1,236/1,315), Midwest 70.0% (1,351/1,930), Northeast 68.1% (4,142/6,081), South 54.5% (2,863/5,254), and Southeast 53.1% (6,111/11,506).

Hospitalizations due to pertussis gradually increased until 2014 and decreased in 2015 (Figure 5(a)). Deaths due to pertussis (Figure 5(b)), involved mainly children <1 year of age (97.6%, 405/415). Among the five geographical regions of Brazil, Midwest and North regions had the highest case fatality rate in the overall population (all ages) ($p < .05$); North region had the highest case fatality rate in children <1 year of age (Table 1).

**Maternal immunization: pertussis vaccine coverage**

In the last quarter of 2014, Tdap vaccination was implemented nationally, yet the vaccination coverage was low. A gradual increase in vaccination coverage was observed in 2015 and 2016 in the South, Midwest, and North region. However, in the other two regions, Southeast and Northeast, although Tdap vaccination coverage was increased in 2015, it was decreased in 2016 (Table 2).

**DISCUSSION**

The present analysis of pertussis surveillance data from the Brazilian Ministry of Health (MoH) showed that from 2010 to 2015, the incidence of pertussis progressively increased in all Brazilian regions. The increase was observed from 2012 onwards with a peak in 2014 and affecting mainly children <1 year of age, which was the age group with the highest case fatality rates. In the two years that followed the NIP recommendation in 2014, Tdap vaccination coverage of pregnant women was low and varying from region to region.

---

Figure 4. Map of Brazil, displaying, by region, the maximum increases in the incidence of pertussis infection in children <1 year of age to peak year, times increased from 2010 (peak year).

Figure 5. Number of (a) hospitalization rates and (b) case fatality rates due to pertussis in Brazil over years. Source data: (A) SIHSUS25 (B) SIM26


Previous data on pertussis incidence and fatality rates in Brazil were published by Guimaraes et al. We extended this information as we included a broader time period [i.e. the year 2015] in our analysis of epidemiological data. Moreover, this is the first study assessing pertussis incidence observing a short period after the implementation of Tdap in the maternal immunization program in Brazil. Furthermore, the present study adds the information on hospitalizations that was lacking in the Guimaraes et al. study.

Our incidence rate data are in agreement with previous studies in Brazil and other countries. In Brazil, Guimaraes et al. reported similar incidence rates for the overall population in 2012–2014. Moreover, the present study further analyzed data by age groups and found that the increase in pertussis incidence, mainly affected children aged <1 year. The Southeast region, where the largest cities are located, has the highest population density (87 people/km²) in the country followed by the South region (50 people/km²); therefore, it is reasonable to record the highest numbers of pertussis cases, hospitalizations, and deaths.

Similar increase in pertussis incidence from 2007 to 2013 was reported by Torres et al. for the state of Parana, where 67.5% of pertussis cases were children <1 year of age. With respect to other countries epidemiological data, year-to-year comparisons are not feasible because of the cyclical appearance of the disease but also because of differences in the epidemiological surveillance capacity and disease confirmation criteria. Furthermore, when interpreting pertussis epidemiological data, we should take into account its evolution in cycles and the increase of the use of biological diagnosis.

The epidemiological data from this study showed that nearly all deaths and hospitalizations due to pertussis in Brazil were in children <1 year of age. We found that the hospitalization rates are very high in Brazil. This might be related to disease seasonality in the country and coincides with the introduction of the DTwP-Hib-HBV to the NIP in 2012. Also, this could hinder a bias towards reporting only the more severe pertussis cases, then an underreporting of pertussis cases is also possible. For example, comparing with the US, the hospitalization rate in Brazil was approximately six or nine times higher [US respective hospitalization rates due to pertussis: 9.9% among cases reported to the national surveillance system during 2000–2016, and 6.9% in the latest provisional surveillance report]. However, cross-country comparisons should be cautious, given the differences in variables affecting diseases’ epidemiology and the differences in the surveillance systems. The hospitalization rate varied by regions and exceeded 50% in children <1 year of age in all Brazilian regions, reflecting the severity of the cases. This is in line with the data of Mancaneira et al. showing that in the period 2011–2013 pertussis-related hospital admissions increased by 242% compared to 1996–2010, and most involved children <1 year of age; deaths due to pertussis had a growing temporal trend from 2011 to 2013. We found the highest mortality rate in the North and lowest in the South, in agreement with Guimaraes et al. who recorded an overall mortality rate of 2.1%, highest in the North region (2.47) and lowest in the South (1.31). The differences in hospitalization and mortality rates between the regions may be explained by the different socioeconomic conditions, including care and access to health services and laboratory facilities for cases confirmation and sample examination.

### Immunization in pregnancy

To the best of our knowledge, vaccination coverage of pregnant women was not previously assessed. In Brazil, the NIP has recently modified the vaccination notification protocol and this might affect the number of notifications as the health professionals have to adapt themselves to the new system; moreover different issues related to the new system’s operationalization/implementation may have emerged in the country. However, the Tdap maternal immunization coverage in the period of our study did not exceed 50% in the year after introduction and this is undoubtedly a worrying situation, considering the increased incidence of pertussis demonstrated here, affecting mainly children<1 year of age. The study of Druzian et al. reported that 35% of pertussis cases in Mato Grosso do Sul during the decade 1999–2008, involved children not yet eligible for primary vaccination as they were <2 months of age. At that time Tdap maternal immunization was not available, which according to WHO is likely the best additional strategy for preventing pertussis in infants too young for vaccination. However, even with low coverage (9.2% in 2014, 40.4% in 2015) an impact may be suspected as in 2015 the study recorded a decline in all epidemiological measures assessed, in particular, the incidence rate dropped from 175.20 per 100,000 in 2014 to 64.93 in 2015. In agreement with this, a study for the state of São Paulo, reported a non-significant decline of pertussis cases in 2015, in infants <2 months of age that was attributed to the impact of maternal vaccination.

Low maternal immunization coverage has also been reported in other countries: 25.6% (95% confidence interval [CI], 24.1–26.1%) was recorded in 2015, a year after the implementation of maternal immunization in Catalonia, Spain, and 39.2% (95% confidence interval [CI], 38.1–40.3%) was reported in 2016. The highest numbers of pertussis cases, hospitalizations, and deaths due to pertussis: 9.9% among cases reported to the national surveillance system during 2000–2016, and 6.9% in the latest provisional surveillance report. However, cross-country comparisons should be cautious, given the differences in variables affecting diseases’ epidemiology and the differences in the surveillance systems. The hospitalization rate varied by regions and exceeded 50% in children <1 year of age in all Brazilian regions, reflecting the severity of the cases. This is in line with the data of Mancaneira et al. showing that in the period 2011–2013 pertussis-related hospital admissions increased by 242% compared to 1996–2010, and most involved children <1 year of age; deaths due to pertussis had a growing temporal trend from 2011 to 2013. We found the highest mortality rate in the North and lowest in the South, in agreement with Guimaraes et al. who recorded an overall mortality rate of 2.1%, highest in the North region (2.47) and lowest in the South (1.31). The differences in hospitalization and mortality rates between the regions may be explained by the different socioeconomic conditions, including care and access to health services and laboratory facilities for cases confirmation and sample examination.

### Table 2. Maternal vaccination coverage with Tdap in Brazil and by region from 2014 to 2016.

| Region  | 2014 | 2015 | 2016 |
|---------|------|------|------|
| Southeast | 10.3 | 0.55 | 3.24 |
| Northeast | 10.3 | 0.41 | 3.63 |
| South | 6.3 | 2.6 | 0.3 |
| Midwest | 10.2 | 3.17 | 4.57 |
| North | 5.1 | 2.39 | 2.83 |

Source data: SI-PNI

Footnote: *calculated by DATASUS based on their records as follows: number of women vaccinated/number of women in the target population X 100; ‡p < 0.05 (South and North Regions compared to the Southeast, Northeast and Midwest Regions; X² test); *p < 0.05 (each of the Brazilian regions compared to the Southeast Region; X² test); †p < 0.05 (each of the Brazilian regions compared to the Midwest region; X² test)
CI, 33.2–45.6%) coverage in 2014 was reported in Belgium.\textsuperscript{45} However, in the US, coverage was gradually increasing from its introduction in 2012,\textsuperscript{46} to reach 53% in 2015 among the general population of pregnant women participating to the Birth Defect Study,\textsuperscript{47} and 53.2% in 2016 among privately insured pregnant women.\textsuperscript{48} In Argentina, maternal immunization coverage was 50.9%, and 67.2% in the first and second year following its introduction by the MoH in 2012, representing an increase of 16.3% (95%CI, 16.1–16.4%).\textsuperscript{49} Furthermore, in the United Kingdom, maternal vaccination coverage is routinely about 60%.\textsuperscript{50} Reasons for the low immunization rate in pregnant women include women’s lack of knowledge about pertussis disease and its possible repercussions for their children, worries over vaccine safety issues,\textsuperscript{51} insurance coverage issues, premature delivery,\textsuperscript{52} lack of direct recommendations from a health-care provider, and little knowledge, or lack of provision of information on immunization protocols during pregnancy to medical assistants such as midwives.\textsuperscript{53} Maternal immunization is a relatively new concept and pregnant women are still reluctant to take any medication during pregnancy. Also, they usually feel healthy themselves and are unaware of the immunization requirements throughout an adult’s life.\textsuperscript{54} Furthermore, in Brazil, pertussis is considered a child disease and its impact in newborns is underestimated. This notion has possibly contributed, with all the factors mentioned above, to the 2016 decrease (33.8%) in maternal immunization coverage. Other factors include the absence of extensive Brazilian guidelines on maternal vaccination and, possibly, the lack of related educational programs for health-care professionals and pregnant women.

Future perspectives

Improving vaccination strategies especially for Tdap maternal immunization and vaccinations of newborns are currently among the key factors towards controlling pertussis.\textsuperscript{55} To improve maternal immunization coverage, vaccine promotion has been suggested, addressing safety concerns and emphasizing disease severity in infancy.\textsuperscript{56} Moreover, to effectively address the problem, we need to understand the main factors contributing to it; this could be answered in future studies designed to assess knowledge, attitudes, and practices related to maternal immunization among pregnant women and health-care professionals. Furthermore, we should put our efforts to improve vaccine coverage of children as well as timely administration of the vaccine, and we need to raise awareness on the severity of the disease. In case of increased incidence during the next pertussis cycle, the additional strategies of maternal immunization, cocooning, booster dose in adolescent/adults or health-care worker vaccination should be used as recommended by the WHO\textsuperscript{41} and by the Global Pertussis Initiative.\textsuperscript{57}

There is a need to improve surveillance systems and laboratory capacity and access to enhance our understanding of pertussis epidemiology and provide valuable information to the research for new vaccines.\textsuperscript{58} Evaluating Brazil’s surveillance system, Teixeira et al.\textsuperscript{59} suggested improvements including integration between different health services, crisis management protocols, and increase personnel training.\textsuperscript{56} Lightly populated areas of the borders with limited ability to employ highly trained professionals could use high technology information surveillance networks offering real-time reporting of cases and easing communication between teams at state and national level.\textsuperscript{56,21} Lastly, Netto et al.\textsuperscript{34} suggested that Brazil’s surveillance system would benefit from a process evaluating its performance at the state level that could inform on local problems needing to be addressed.\textsuperscript{34} It is important to enhance the training of the health-care professionals on all aspects of their dual role as patients’ educators and as responsible for notifying pertussis cases to the surveillance systems.

Limitations

As with any study analyzing surveillance datasets, this analysis inherits the shortcomings of the databases used. Therefore, there is a potential of bias in data derived from secondary databases due to an accurate recording while underreporting in SINAN of diseases, hospitalizations, and deaths have been raised in previous studies.\textsuperscript{22,23} Although Brazil has a national informatics system (DATASUS) with different databanks, it still struggles with data sub-notification and reliability on the data, there are still municipalities areas with no access to computer which could affect notifications and therefore introduce artificial differences in disease’s incidence.\textsuperscript{43} SIM and SINAN have shown in the past variable reporting efficiency between different regions.\textsuperscript{27} Studies have recorded failure in adequately reporting important disease variables in SINAN database; however, the limitations are acknowledged and since its introduction SINAN was undergone several modifications to improve system’s efficacy.\textsuperscript{57,58} Therefore, surveillance epidemiological data require time for validation, thus 2016 epidemiological data were still under review at the time of this analysis. However, 2016 Tdap vaccination coverage data had been verified and available for analyses. Furthermore, pertussis is difficult to diagnose, especially in adults, and many cases may therefore not have been reported to authorities which means that the numbers here may well underestimate the real extent of the problem. Changes in diagnostic methods might have also affected the rate of reporting; the progressive introduction of a PCR method for diagnosis in some states as São Paulo (in 2009), Paraná and Bahia (in 2014) might have increased the number of notified cases.\textsuperscript{20,43,60,61} Our analysis is focused in children <4 years of age which comprised the 77% of all cases, the rest 23% contains all other ages and thus we may not draw conclusions related to other age groups of interest such as adults and young women. Furthermore, the database’s information on the vaccination status and timing were not verified with the vaccination booklet. Therefore, the children with pertussis between 1y and 4y were maybe incompletely vaccinated, or not vaccinated on time. Although this type of information is predicted to be included in the updated Brazilian vaccination notification protocol\textsuperscript{40} full implementation of this process will take time. At last, the surveillance system is lacking the information on the status of Tdap vaccination during pregnancy of the mothers with diseased children <1 year of age.
Conclusions
This study’s epidemiological findings demonstrate that pertussis is still an important public health issue. A high mortality rate amongst very young children is the undesirable consequence of the increased incidence of pertussis, reflecting its seriousness. Inclusion of Tdap vaccination in the maternal immunization program in 2014 was a critical strategy, however, uptake has been slow and co-ordinated efforts and national plans are needed to increase awareness and maternal immunization coverage.

Methods
Pertussis disease appears on the list of diseases of compulsory notification of the Health Surveillance Secretariat of the MoH. The disease is listed under the code A 37.0 as per the International Classification of Diseases, version 10 (ICD 10). In Brazil, the reporting of all suspected pertussis cases is obligatory. The healthcare professionals are responsible to notify the surveillance systems through standardized electronic forms containing all relevant information, including demographics, vaccination status, hospitalizations, and death. This analysis used the “confirmed pertussis cases” (suspected cases were not available) collected between 2010 and 2015 which include laboratory, clinical or epidemiologically confirmed cases from the following nationwide information systems of the MoH: the National Information System for Notifiable Diseases, (SINAN, Sistema de Informação de Agravos de Notificação), the Hospitalization Information System (SIH, Sistema de Informações Hospitalares), and the Mortality Information System (SIM, Sistema de Informações sobre Mortalidade).

Furthermore, we used data collected between 2014 and 2016 from Brazil’s Unified Health System (SUS, Sistema Único de Saúde) on the vaccination of pregnant women from the Information system of the National Immunization Program (SI-PNI, Sistema de Informação do Programa Nacional de Imunizações). Because Tdap maternal immunization was introduced in late 2014 (November), we decided to analyze data from at least two years after implementation (Nov 2014–Dec 2016), although we could not include 2016 epidemiological data as these were still under review.

Variables and outcomes
The extracted data were a) the number of cases with pertussis infection, b) the number of hospitalizations and mortality due to pertussis, c) pertussis vaccination coverage (Tdap), d) geographical distribution of pertussis cases, and e) age at disease onset.

Outcomes included a) epidemiological data by geographical region, year, and age group, and b) Tdap coverage in pregnant women.

Statistical analysis
The programs Excel, Medcalc, and SPSS version 20.0 were used. The chi-square test was used to compare proportions, and the Student’s t-test for independent samples to compare means. In all analyses, a level of significance of $p < .05$ was considered statistically significant.

Highlights
- Our recent data showed an increase of pertussis incidence between 2010 and 2014 but a decrease in 2015, confirming a pertussis cycle as in other countries
- Most cases and deaths occurred in children <1 year of age
- Maternal vaccination coverage was around 40% in 2015 but decreased in 2016, correlating with the decrease of the pertussis cycle and probably with a decrease of information concerning the severity of the disease

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| CI           | confidence interval |
| DTP          | diphtheria tetanus pertussis vaccine |
| DTwP-Hib-HBV | diphtheria tetanus whole pertussis - H. influenza type B - hepatitis B vaccine |
| MoH          | Ministry of Health |
| NIP          | National Immunization Program |
| SIH          | Sistema de informações Hospitalares |
| SIM          | Sistema de Informação sobre Mortalidade |
| SUS          | Sistema Único de Saúde |
| SINAN        | Sistema de Informação de Agravos de Notificação |
| SI-PNI       | Sistema de Informação do Programa Nacional de Imunizações |
| Tdap         | diphtheria tetanus acellular pertussis vaccine |
| US           | United States |

Acknowledgments
Authors would like to thank Evely Tanaka (employed by GSK at the time of the study) for her contribution to the study. They also thank Business & Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Vincent Laporte coordinated manuscript development and editorial support, and Athanasia Benekou provided medical writing support.

Contributorship
All authors participated in the design or implementation or analysis, and interpretation of the study; and the development of this manuscript. All authors had full access to the data and gave final approval before submission.

Disclosure of potential conflicts of interest
Ariane de Jesus Lopes de Abreu is employed by Shift Gestão de Serviços and reports to be a third part employee for the GSK group of companies. Eliana Noqueira Castro de Barros, Otávio Cintra, and Bárbara Emoingt Furtado are employees of the GSK group of companies. Eliana Noqueira Castro de Barros, Barbara Furtado, and Otávio Cintra hold stock options in the GSK group of companies. Eduardo Barbosa Coelho, Altacílio Aparecido Nunes, and Monica Cintra report their institution received funding from the GSK group of companies to complete the work disclosed in this manuscript, as well as funding outside the submitted work.

Data statement
This study focused on gathering evidences related to pertussis burden of disease before and after Tdap vaccine introduction in the National Immunization Program. The epidemiological data analysis is focused to...
complement the literature data, using the Ministry of Health public databases (SINAN, Sistema de Informação de Agravos de Notificação; SIH, Sistema de Informações Hospitalares; and SIM, Sistema de Informação sobre Mortalidade), demonstrating the importance of new preventive strategies against pertussis in vulnerable populations (in special, children <1 year of age).

**Funding**

GlaxoSmithKline Biologicals S.A. funded this study (GSK study identifier HO-16-17848) and all costs related to the development of related publications.

**ORCID**

Ariane De Jesus Lopes De Abreu [http://orcid.org/0000-0002-5599-0991](http://orcid.org/0000-0002-5599-0991)

Eduardo Barbosa Coelho [http://orcid.org/0000-0003-3491-3396](http://orcid.org/0000-0003-3491-3396)

**References**

1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18:326–82.

2. Melvin JA, Scheller EV, Miller JF, Cotter PA. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol. 2014;12:274–88.

3. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog. 2005;1:e45.

4. Lynfield R, Schaffner W. Can we conquer coqueluche? J Infect Dis. 2014;209:S1–33.

5. World Health Organization (WHO). Pertussis vaccines: WHO position paper. 2015 [accessed 2018 Feb 25]. [http://www.who.int/wer/2015/wer9035.pdf?ua=1](http://www.who.int/wer/2015/wer9035.pdf?ua=1)

6. Gabuttì G, Azzari C, Bonanni P, Prato R, Tozzi AE, Zanetti A, Zuccotti G. Pertussis: current perspectives on epidemiology and prevention. Hum Vaccin Immunother. 2015;11:108–17.

7. Spector TB, Maziarz EK. Pertussis. Med Clin North Am. 2013;97:537–52.

8. Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing the cocoon strategy. Vaccine. 2013;31:618–25.

9. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24:S58–S61.

10. World Health Organization (WHO). The immunological basis for immunization series: module 4: pertussis. 2017 [accessed 2019 Mar 20]. [https://apps.who.int/iris/handle/10665/259388](https://apps.who.int/iris/handle/10665/259388)

11. Ministerio da Saúde. Calendario Nacional deVacinação. 2018 [accessed 2018 June 19]. [http://portais.saude.gov.br/acesso-e-programas/vacinacao/calendario-nacional-de-vacinacao](http://portais.saude.gov.br/acesso-e-programas/vacinacao/calendario-nacional-de-vacinacao)

12. Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, Andrews N. sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis. 2016;63:S23–S243.

13. Feldstein R, Mariat S, Gacic-Dobo M, Díaz MS, Conklin LM, Wallace AS. Global routine vaccination coverage, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:1252–55.

14. Locht C. Pertussis: where did we go wrong and what can we do about it? J Infect. 2016;72:S34–50.

15. Tan T, Dalby T, Forsyth K, Halperin SA, Heusinger U, Hozbgor D, Plotkin S, Ulla-Ouat-Gutierrez R, Wirsing von Konig CH. Pertussis across the globe: recent epidemiologic trends from 2000 to 2013. Pediatr Infect Dis J. 2015;34:e222–e232.

16. World Health Organization-Strategic Advisory Group of Experts (WHO - SAGE). Working group on pertussis vaccines. Backgound paper. 2014 [accessed 2018 Nov 4]. [http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_back ground_FINALA4_web.pdf?ua=1](http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINALA4_web.pdf?ua=1)

17. Burns DL, Meade BD, Messionnier NE. Pertussis resurgence: perspectives from the working group meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J Infect Dis. 2014;209:S32–S35.

18. Amirthalingam G. Strategies to control pertussis in infants. Arch Dis Child. 2013;98:552–55.

19. Spokes PJ, Quinn HE, McAnulty JM. Review of the 2008–2009 pertussis epidemic in NSW: notifications and hospitalisations. N S W Public Health Bull. 2010;21:167–73.

20. Guimarães LM, Carneiro EL, Carvalho-Costa FA. Increasing incidence of pertussis in Brazil: a retrospective study using surveillance data. BMC Infect Dis. 2015;15:442.

21. Heil J, Ter Waarbeek HLG, Hoebe CJP, Jacobs PHA, van Dam DW, Trienekens TAM, Cals JLW, van Loo IJM, Dukers-Muijers NHTM. Pertussis surveillance and control: exploring variations and delays in testing, laboratory diagnostics and public health service notifications, the Netherlands, 2010 to 2013. Euro Surveill. 2017;22(28):30571. doi:10.2807/1560-7917.ES.2017.22.28.30571. PubMed PMID: 28749331; PubMed Central PMCID: PMC5545763.

22. Tiago ZDS, Picoli RP, Graeff SV, Cunha RVD, Arantes R. Underreporting of gestational, congenital and acquired syphilis among indigenous peoples in Mato Grosso do Sul State, Brazil, 2011–2014. Epidemiol Serv Saude. 2017;26:503–12.

23. Maia DAB, Farias PG, Assunção RS, Vidal SA. Evaluation of the implantation of the notifiable diseases information system in Pernambuco state, Brazil, 2014. Epidemiol Serv Saude. 2019;28:e201817.

24. Ramírez PM, Longoria L, Saracho JS, Román PR. Underreporting of gestational, congenital and acquired syphilis among indigenous peoples in Mato Grosso do Sul State, Brazil, 2011–2014. Epidemiol Serv Saude. 2017;26:503–12.

25. Sistema Único de Saúde (SUS). Portal da Saude - SIHSUS. 2017 [accessed 2017 Nov 30]. [http://www2.datasus.gov.br/DATASUS/index.php?area=0901&item=1&acao=c25](http://www2.datasus.gov.br/DATASUS/index.php?area=0901&item=1&acao=c25)

26. Sistema de Informação de Agravos de Notificação (SINAN). Sistema de Informação de Agravos de Notificação, Dados Epidemiológicos. 2017 [accessed 2017 Nov 29]. [http://portais nan.saude.gov.br/dados-epidemiologicos-sinan](http://portais nan.saude.gov.br/dados-epidemiologicos-sinan)

27. Ministério da Saúde. Brasile 2013. Uma análise da situação de saúde e das doenças transmissíveis relacionadas a pobreza. 2014 [accessed 2018 July 18]. [http://bvsms.saude.gov.br/bvs/publica coes/saude_brasil_2013_analise_situacao_saude.pdf](http://bvsms.saude.gov.br/bvs/publicacoes/saude_brasil_2013_analise_situacao_saude.pdf)

28. WorldAtlas. The five regions of Brazil. [accessed 20 March 2019]. [https://www.worldatlas.com/articles/the-five-regions-of-brazil.html](https://www.worldatlas.com/articles/the-five-regions-of-brazil.html)

29. Torres RS, Santos TZ, Torres RA, Pereira VV, Favero LA, M. Filho OR, Penkal ML, Araujo LS. Resurgence of pertussis at the age of vaccination: clinical, epidemiological, and molecular aspects. J Pediatr (Rio J). 2015;91:333–38.

30. World Health Organization (WHO). Laboratory manual for the diagnosis of whooping cough caused by bordetella pertussis/bordetella parapertussis: update 2014. [accessed 2019 Mar 20]. [https://apps.who.int/iris/handle/10665/127891](https://apps.who.int/iris/handle/10665/127891)

31. Skoff TH, Hadler S, Hariri S. The epidemiology of nationally reported pertussis in the United States, 2000–2016. Clin Infect Dis. 2019;68(10):1634–1640. doi:10.1093/cid/ciy757.

32. Centers for Disease Control and Prevention (CDC). Provisional 2018 report of notifiable diseases: pertussis. 2019 [accessed 2019 May 9]. [https://www.cdc.gov/pertussis/downloads/pertussis-surv-report-2018-508.pdf](https://www.cdc.gov/pertussis/downloads/pertussis-surv-report-2018-508.pdf)

33. Mancaneira JF, Benedetti JR, Zhang L. Hospitalizations and deaths due to pertussis in children from 1996 to 2013. J Pediatr (Rio J). 2016;92:40-45.
national conference on health surveillance. Cien Saude Colet. 2017;22:3137–48.
35. Druzin AF, Brustoloni YM, Oliveira SM, Matos VT, Negri AC, Pinto CS, Asato S, Urias Cdos S, Paniglio AM. Pertussis in the central-west region of Brazil: one decade study. Braz J Infect Dis. 2014;18:176–81.
36. Berezin EN, de Moraes JC, Leite D, Carvalhanas TR, Yu AL, Blanco RM, Rodrigues M, Almeida FJ, Bricks LF. Sources of pertussis infection in young babies from Sao Paulo State, Brazil. Pediatri Infect Dis J. 2014;33:1289–91.
37. Pimentel AM, Baptista PN, Ximenes RA, Rodrigues LC, Magalhaes V, Silva AR, Souza NF, Matos DG, Pessoa AK. Pertussis may be the cause of prolonged cough in adolescents and adults in the interepidemic period. Braz J Infect Dis. 2015;19:43–46.
38. Sutter RW, Cochi SL. Pertussis hospitalizations and mortality in the United States, 1985–1988. Evaluation of the completeness of national reporting. JAMA. 1992;267:386–91.
39. Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths from pertussis are underestimated in England. Arch Dis Child. 2002;86:336–38.
40. Ministério da Saúde. Nota Informativa No 47/2018-CGPNI /DEVT/SVS/MS. 2018 [accessed 2018 July 18]. http://portais.saude.gov.br/images/pdf/2018/marco/16/SEI-MS-2835675-Nota-Informativa-47-2018-integracao-SIPNEx-e-SUS-AB.pdf
41. World Health Organization (WHO). Pertussis vaccines: WHO position paper, August 2015—recommendations. Vaccine 2016;34:1423–25.
42. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Fry NK, Ramsay M. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin Infect Dis. 2015;60:333–37.
43. Fernandes EG, Sartori AMC, de Soarez PC, Carvalhanas TRMP, Rodrigues M, Novaes HMD. Challenges of interpreting epidemiologic surveillance pertussis data with changing diagnostic and immunization practices: the case of the state of Sao Paulo, Brazil. BMC Infect Dis. 2018;18:126.
44. Fernandez-Canio MI, Espada-Trespalacios X, Reyes-Lacalle A, Manresa Dominguez JM, Armadans-Gil L, Campins-Marti M, Falguera-Puig G, Toran Monserrat P. Vaccination coverage against pertussis in pregnant women of Catalonia in the first year of implementation of the immunisation program. Enferm Infec Microbiol Clin. 2017;35:550–55.
45. Laenen J, Roelants M, Devlieger R, Vandermeulen C. Influenza and pertussis vaccination coverage in pregnant women. Vaccine. 2015;33:2125–31.
46. Sawyer M, Liang JL, Messionnier NE, Clark TA. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women — advisory committee on immunization practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62:131–35.
47. Kerr S, Van Bennekom CM, Liang JL, Mitchell AA. Tdap vaccination coverage during pregnancy - selected sites, United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66:1105–08.
48. Zhou F, Xu J, Black CL, Ding H, Cho BH, Lu Pj, Lindley MC. Trends in Tdap vaccination among privately insured pregnant women in the United States, 2009–2016. Vaccine. 2019;37:1972–77.
49. Vizzotti C, Juarez MV, Bergel E, Romanin V, Califano G, Sagradini S, Rancano C, Aquino A, Librter R, Polack FP, et al. Impact of a maternal immunization program against pertussis in a developing country. Vaccine. 2016;34:6223–28.
50. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014;384:1521–28.
51. Gkentzi D, Katsakiori P, Marangos M, Hsia Y, Amirthalingam G, Heath PT, Ladhani S. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed. 2017;102:F456–F463.
52. Healy CM. Pertussis vaccination in pregnancy. Hum Vaccin Immunother. 2016;12:1972–81.
53. Saadatian-Elahi M, Plotkin S, Mills KHG, Halperin SA, McIntyre PB, Picot V, Louis J, Johnson DR. Pertussis: biology, epidemiology and prevention. Vaccine. 2016;34:5819–26.
54. Chamberlain AT, Seib K, Ault KA, Orenstein WA, Frew PM, Malik F, Cortes M, Copa P, Whitney EA, Flowers LC, et al. Factors associated with intention to receive influenza and tetanus, diphtheria, and acellular pertussis (Tdap) vaccines during pregnancy: a focus on vaccine hesitancy and perceptions of disease severity and vaccine safety. PLoS Curr. 2015;7:currents.outbreaks.d37b1bceebae5a7a0640a301ca819.
doi:10.1371/currents.outbreaks.d37b1bceebae5a7a0640a301ca819. PubMed PMID: 25789203; PubMed Central PMCID: PMC4353696.
55. Forsyth K, Plotkin S, Tan T, Wirsing von Konig CH. Strategies to decrease pertussis transmission to infants. Pediatrics. 2015;135:e1475–1482.
56. Teixeira MG, Costa MC, Souza LP, Nascimento EM, Barreto ML, Barbosa N, Carmo EH. Evaluation of Brazil’s public health surveillance system within the context of the international health regulations (2005). Rev Panam Salud Publica. 2012;32:49–55.
57. Ministério da Saúde. A experiencia brasileira em sistemas de informacao em saude. 2009 [accessed 2018 July 18]. http://bvsms.saude.gov.br/bvs/publicacoes/experiencia_brasileira_sistema_sao_volume1.pdf
58. Ministério da Saúde., Organização Pan-Americana de Saúde., Fundação Oswaldo Cruz. A experiencia brasileira em sistemas de informacao em saude. 2009 [accessed 2019 May 17]. http://bvsms.saude.gov.br/bvs/publicacoes/experiencia_brasileira_sistema_sao_volume2.pdf
59. Crabbe H, Saavedra-Campos M, Verlander NQ, Leonard A, Morris J, Wright A, Balasegaram S. Are pertussis cases reported too late for public health interventions? Retrospective analysis of cases in London and South East England, 2010 to 2015. Euro Surveill. 2017;22(29):30577. doi:10.2807/1560-7917.EV.2017.22.29.30577. PubMed PMID: 28749334; PubMed Central PMCID: PMC5532964.
60. Centers for Disease Control and Prevention (CDC). Pertussis (Whooping Cough) - Brazil. 2017 [accessed 2019 May 9]. https://www.cdc.gov/pertussis/countries/lapp-brazil.html
61. Almeida AF, Flor-de-Lima F, Simoes JS, Castro C, Tavares M. Pertussis in a Portuguese pediatric tertiary care hospital. Pediatr Infect Dis J. 2016;35:466–67.
62. Sistema de Informação do Programa Nacional de Imunizações (SI-PNI). Sistema de Informacao do programa nacional de informacoes. 2017 [accessed 2017 Nov 29]. http://pni.datasus.gov.br/
63. Ministério da Saúde. Informe Técnico para Implantação da Vacina Adsorvida Difteria, Tétano e Coqueluche (Pertussis Acelular) Tipo adulto - dTpa. 2014 [accessed 2009 May 17]. http://portalarquivos2.saude.gov.br/images/pdf/2015/junho/26/Informe-T--cnicodTpa-2014.pdf